The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?

To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. 213 consecutive LGG patients...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2018-07, Vol.14 (16), p.1559-1567
Main Authors: Franceschi, Enrico, Mura, Antonella, De Biase, Dario, Tallini, Giovanni, Pession, Annalisa, Foschini, Maria Pia, Danieli, Daniela, Pizzolitto, Stefano, Zunarelli, Elena, Lanza, Giovanni, Bartolini, Daniela, Silini, Enrico Maria, Visani, Michela, Di Oto, Enrico, Tosoni, Alicia, Minichillo, Santino, Lamberti, Giuseppe, Lanese, Andrea, Paccapelo, Alexandro, Bartolini, Stefania, Brandes, Alba A
Format: Article
Language:English
Subjects:
1/2
1p19q co-deletion
Age
Biomarkers
Brain cancer
Chemotherapy
Deoxyribonucleic acid
DNA
DNA methylation
Glioma
low-grade gliomas
Medical prognosis
methylation
Mutation
NGS
Radiation therapy
Risk assessment
Studies
Surgery
treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. 1/2 mutation, 1p/19q co-deletion, methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0634